Article Text
PDF
Abstract
Neuroendocrine tumours (NETs) of the urinary tract are rare, and the urinary bladder is the the most common primary site. Primary ureteric NET is rarer with under 80 cases reported in the literature thus far. Most of these tumours are of the high-grade small cell neuroendocrine carcinoma subtype, which has a worse prognosis. Neoadjuvant chemotherapy has a proven role in the management of NET of the bladder as it downstages the tumour, which may add to significant recurrence-free survival and overall survival. We report the successful management of a patient with locally advanced small cell neuroendocrine carcinoma of the ureter, who had a pathological complete response after neoadjuvant chemotherapy with etoposide and cisplatin. He subsequently received adjuvant chemotherapy followed by radiation and is recurrence-free at a follow-up of 1 year.
- haematuria
- urological cancer
- urological surgery
Statistics from Altmetric.com
Footnotes
Contributors NTJ and AJ planned the management. MF was primarily involved in the preoperative and postoperative management of the patient and prepared the manuscript under NTJ’s guidance. NTJ was the chief surgeon who operated on the patient and was following the patient along with MF. SD made the pathological diagnosis and wrote the pathological part of the manuscript. He received chemotherapy under AJ’s supervision.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.